Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P190009/S012

OPRA Implant System

Integrum AB · Decision date Feb 12, 2026

FDA DECISIONP190009/S012

What did the FDA decide?

FDA records P190009/S012 as a supplement to PMA P190009, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 12, 2026.

FDA approval order statement

the replacement of the current laser machine used to create the BioHelix surface with a comparable machine in the manufacturing process.
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Orthopedic
Decision date
Feb 12, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P190009/S012
Regulatory pathway
PMA supplement
Applicant
Integrum AB
Product code
PJY
Decision code
OK30
Decision date
Feb 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Osseoanchored prostheses for the rehabilitation of transfemoral amputees.

Applicant
Integrum AB
Product code
PJY
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P190009/S006 · Related supplement

    OPRA Implant System, Abutment component

  2. P190009/S012 received

    Application receipt date recorded by FDA.

  3. P190009/S012 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P190009. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P190009

Product / regulatory recordCompanyPathwayDecision dateSource
Integrum ABPMA supplementAug 14, 2025FDA
Integrum ABPMA supplementNov 20, 2025FDA
Integrum ABPMA supplementMar 12, 2026FDA
Integrum ABPMA supplementApr 15, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Integrum AB

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Krokslatts Fabriker 50, Mölndal, SE-431 37

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records